Axicabtagene-ciloleucel/lisocabtagene-maraleucel/tisagenlecleucelVarious toxicities

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2024年 / 1999卷 / 1期
关键词：
D O I：
10.1007/s40278-024-54375-1
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：66 / 66
相关论文
共 50 条
  • [31] Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis (vol 11, 698607, 2021)
    Meng, Jun
    Wu, XiaoQin
    Sun, Zhen
    Xun, RenDe
    Liu, MengSi
    Hu, Rui
    Huang, JianChao
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [32] Cost-Effectiveness of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Treatment of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
    Parker, Christopher
    Liu, Fei Fei
    Deger, Kristen
    Franco-Villalobos, Conrado
    Proskorovsky, Irina
    Keating, Scott J.
    Sorensen, Sonja
    Dorman, Emily
    BLOOD, 2021, 138
  • [33] Predictors of response to axicabtagene-ciloleucel CAR T cells in aggressive B cell lymphomas: A real-world study
    Iovino, Lorenzo
    Wu, Qian Vicky
    Voutsinas, Jenna
    Panaite, Lorena
    Mullane, Erin
    Lynch, Ryan C.
    Ujjani, Chaitra
    Smith, Stephen D.
    Gopal, Ajay K.
    Till, Brian G.
    Milano, Filippo
    Chow, Victor
    Gauthier, Jordan
    Turtle, Cameron J.
    Maloney, David G.
    Shadman, Mazyar
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2022, 26 (24) : 5976 - 5983
  • [34] Axicabtagene-ciloleucel/brexucabtagene-autoleucel/tisagenlecleucelImmune effector cell-associated neurotoxicity syndrome: 9 case reports
    Reactions Weekly, 2023, 1941 (1) : 84 - 84
  • [35] Cytokine Monitoring in R/R DLBCL Patients Treated With Axicabtagene Ciloleucel: Associations With Toxicities and Outcomes
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (05) : 17 - 19
  • [36] Axicabtagene-ciloleucel/DexamethasoneCytokine release syndrome, immune effector cell-associated neurotoxicity syndrome and lack of efficacy: case report
    Reactions Weekly, 2024, 2025 (1) : 64 - 64
  • [37] Antineoplastics/axicabtagene-ciloleucel/CAR-T-cell-therapiesFalse positive HIV test results and lack of efficacy: case report
    Reactions Weekly, 2023, 1954 (1) : 71 - 71
  • [38] Determination of CAR-T cells in CSF by flow cytometry in patients with relapsed lymphoma undergoing tisagenlecleucel or axicabtagene-ciloleucel therapy
    Thavayogarajah, T.
    Hockl, P.
    Mueller, A.
    Balabanov, S.
    Roth, P.
    Schanz, U.
    Widmer, C. C.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 241 - 242
  • [39] Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Vs Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
    Maloney, David G.
    Kuruvilla, John
    Fox, Christopher P.
    Cartron, Guillaume
    Li, Daniel
    Hasskarl, Jens
    Bonner, Ashley
    Zhang, Yixie
    Liu, Fei Fei
    BLOOD, 2020, 136
  • [40] Axicabtagene-ciloleucel/ciltacabtagene-autoleucel/tisagenlecleucelCytokine release syndrome, immune effector cell-associated neurologic syndromes and lack of efficacy
    Reactions Weekly, 2024, 1998 (1) : 94 - 94
12345